Delivery Order SPE2DB22D3010-SPE2DB25FP2SG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement therapy medication. This firm fixed-price delivery order, valued at $1,856.40, was issued without a set-aside designation and is scheduled for completion by June 26, 2025. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for 24,000 units of Creon DR 100s capsules, a pancreatic enzyme supplement medication. This competitively awarded, non-set-aside contract carries a ceiling value of $3,042.77 and is classified as a firm fixed price delivery order with an ultimate completion date of August 27, 2025. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Creon DR 36,000 unit capsules in units of 100, with a contract ceiling value of $2,335.13 and an ultimate completion date of July 24, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement therapy medication. This firm fixed-price delivery order, valued at $5,910.78, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award is non-competitive set-aside and will be performed at the vendor's corporate office location...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of 36,000 units of Creon DR 100 capsules, a pancreatic enzyme replacement therapy commonly used to treat pancreatic insufficiency. This firm fixed-price delivery order, valued at $21,355.66 with an ultimate completion date of August 7, 2025, represents a non-competitive award under an existing contract vehicle. The award was fulfilled by AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 12,000 unit capsules of Creon DR 100s, a pancreatic enzyme replacement medication, valued at $2,945.06. The contract is a firm fixed-price delivery order with an ultimate completion date of September 17, 2025, and represents a non-set-aside competitive award. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $35,129.07 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for 36,000 unit capsules of Creon, a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency. This competitive award, which is not set-aside, represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- SPE2DB22D3010Indefinite Delivery Contract
- SPE2DB22D3010-SPE2DB25FP2SGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This competitively awarded, non-set-aside order carries a firm fixed price of $13,340.29 and is scheduled for completion by June 17, 2025. The products will be delivered to the company's headquarters in Conshohocken, Pennsylvania, and serve federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor to the federal government, AmerisourceBergen Drug Corp maintains a comprehensive portfolio of medical product deliveries for military healthcare programs worldwide, encompassing specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 6/16/25 |